AbTis Linker

Technology

AbTis next generation linker

Site-specific (Fc region) conjugation using traceless linker


 

AbTis ADC production by Traceless Linker

(Two simple steps)

 

  1. Antibody-FcBP w/ functional group reaction

    (FcBP release in this step)

  2. Drug w/functional group Addition (Addition of drug-linker)
AbTis Next Generation

AbTis ADC Linker Competitive Edge

Advantage over conventional ADC


 

Drug Conjugation to the unmodified mAb
  • Applicable to the therapeutic antibody with no modification :

    Cost-effective ADC production

Site-specific conjugation
  • Covalent bond with Fc-domain

  • High yield of conjugation and simple process of purification: CMC advantage

Diversity of conjugates
  • Drug-loading control (1~4)

  • Diverse drug conjugation / in-vivo diagnostics

Stable in serum, protease-specific drug release linker
  • Peptide linker with serum stability

  • Valine-Citrulline moiety

위로이동